Screener
Mirum Pharmaceuticals, Inc. MIRM Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalents.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
FAQ
- What is Mirum Pharmaceuticals, Inc.'s restricted cash?
- Mirum Pharmaceuticals, Inc. (MIRM) reported restricted cash of $1.73M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s restricted cash changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s restricted cash increased by 261.3% year-over-year, from $480K to $1.73M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s restricted cash?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s restricted cash has grown at a -75.4% compound annual growth rate (CAGR), from $100M to $1.48M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Mirum Pharmaceuticals, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude